Cislini Jeff sold $337K of RVMD
Cislini Jeff (General Counsel) sold 2,157 shares of Revolution Medicines, Inc. (RVMD) at $156.12 ($0.34M total) on 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan; no new company fundamentals are disclosed.
Market read
Traders may note the insider sale for sentiment/positioning, but it is unlikely to change valuation absent other catalysts.
What to watch
The article provides no context on total compensation, tax-motivated selling, or whether other insiders sold/held; without that, the signal is weak.
Background
The article is a SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).
Ticker impact
Revolution Medicines disclosed a Form 4 showing General Counsel Cislini Jeff sold 2,157 shares at $156.1191 on 2026-06-16 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this disclosure; any impact would be sentiment/positioning related and short-lived.
The filing is an open-market sale by an officer under a pre-arranged Rule 10b5-1 plan, with no accompanying operational/regulatory/financial catalyst described.
Market effects
Minimal—this is company-specific insider transaction disclosure with no sector-wide regulatory/clinical read-across provided.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with management’s risk management or diversification needs; traders may still treat it as a mild bearish sentiment input.
Key entities
- issuerRevolution Medicines, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderCislini Jeff
General Counsel who sold 2,157 shares on 2026-06-16 under a 10b5-1 plan.
